文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

摩尔多瓦耐多药/利福平耐药结核治疗失败患者获得性耐药率高

High rates of acquired resistance to fluoroquinolones, bedaquiline, and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova.
PubMed 文献 · Clin Microbiol Infect · 2025-09-11

该回顾性队列研究分析摩尔多瓦2021-2022年全国MDR/RR-TB监测数据,1034例启动治疗者中55例(5.3%)治疗失败。治疗失败者基线氟喹诺酮类、贝达喹啉、利奈唑胺耐药率显著高于成功治疗者,且39.6%出现获得性耐药。基线氟喹诺酮耐药和获得性耐药与治疗失败相关。

要点

  • MDR/RR-TB治疗失败者基线氟喹诺酮耐药66.7%、贝达喹啉12.5%、利奈唑胺25.0%。
  • 治疗失败者中39.6%出现获得性耐药,成功治疗者无获得性耐药。
  • 基线氟喹诺酮耐药(OR 4.7)和获得性耐药(OR 63.5)与治疗失败相关。

核心结论

  • 尽管含贝达喹啉方案治疗失败率低,但关键二线抗结核药物基线和获得性耐药率高,是治疗失败驱动因素。

研究设计与样本

  • 回顾性队列研究,分析摩尔多瓦2021-2022年全国结核监测数据中1034例启动MDR/RR-TB治疗且具WHO A组药物基线及随访药敏结果的患者。

主要发现

  • 1034例中55例(5.3%)治疗失败,693例(67.1%)成功治疗。
  • 治疗失败者基线耐药率:氟喹诺酮类32/48(66.7%)vs 86/471(18.3%),贝达喹啉6/42(12.5%)vs 3/468(0.6%),利奈唑胺12/48(25.0%)vs 3/468(0.6%),均p<0.0001。
  • 获得性耐药发生于48例治疗失败者中的19例(39.6%),成功治疗者无获得性耐药;贝达喹啉13/42(30.9%)、利奈唑胺6/36(16.7%)、氟喹诺酮类4/16(25.0%)。
  • 基线氟喹诺酮耐药(OR 4.7;95%CI 2.0-11.2)和获得性耐药(OR 63.5;95%CI 7.7-8311.7)与治疗失败相关。

临床怎么用

  • 应加强耐药监测、提高治疗依从性并优化个体化方案,以预防广泛耐药结核出现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mycobacterium tuberculosis with rifampicin resistance ranks among the four critical antimicrobial-resistant pathogens needing priority attention as identified by the World Health Organization (WHO) in 2024. Our objective was to identify the causes of treatment failure in patients diagnosed with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) in a nationwide cohort in the Republic of Moldova, a WHO high-burden country of MDR/RR-TB. METHODS: A retrospective cohort study analysed national tuberculosis surveillance data (2021-2022) on patients diagnosed with MDR/RR-TB with available baseline and follow-up drug susceptibility testing for WHO group A drugs. Treatment failure was defined as the absence of sputum culture conversion after 6 months. Logistic regression was used to identify risk factors associated with treatment failure. RESULTS: Of 1034 patients initiating MDR/RR-TB treatment, 55 (5.3%) experienced treatment failure, whereas 693 (67.1%) were successfully treated. Baseline resistance to WHO group A drugs was significantly higher in patients with treatment failure than in those with successful outcomes: fluoroquinolones (32/48 [66.7%] vs. 86/471 [18.3%]; p < 0.0001), bedaquiline (6/42 [12.5%] vs. 3/468 [0.6%]; p < 0.0001), and linezolid (12/48 [25.0%] vs. 3/468 [0.6%]; p < 0.0001). Acquired resistance occurred in 19 of 48 (39.6%) of those failing treatment, but none with successful outcomes, particularly to bedaquiline 13 of 42 (30.9%), linezolid 6 of 36 (16.7%), and fluoroquinolones 4 of 16 (25.0%). Baseline fluoroquinolone resistance (OR, 4.7; 95% CI, 2.0-11.2) and acquired resistance to any WHO group A drug (OR, 63.5; 95% CI, 7.7-8311.7) were associated with treatment failure. DISCUSSION: Although frequencies of treatment failure in MDR/RR-TB are low on bedaquiline-containing treatment regimens, we find alarmingly high rates of baseline and acquired drug resistance to key second-line anti-TB drugs as a driver for treatment failure in MDR/RR-TB. Strengthening resistance monitoring, improving adherence, and optimizing individualized regimens are urgently needed to prevent the emergence of extensively drug-resistant TB in high-burden settings of MDR/RR-TB.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Chesov D, Reimann M, Mukherjee T, et al. High rates of acquired resistance to fluoroquinolones, bedaquiline, and linezolid in patients failing treatment against drug-resistant tuberculosis in the Republic of Moldova. Clin Microbiol Infect. 2025. PMID: 40945720. doi:10.1016/j.cmi.2025.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。